Dear Editor, I read with interest the commentary by Tannock et al. titled “Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor” (J Clin Oncol 2025;00:1–5) (Tannock et al. 2025). While the authors raise important concerns regarding toxicity and methodological issues in the monarchE and NATALEE trials, we believe a more nuanced perspective is warranted, particularly when considering the number needed to treat (NNT) in context with other established adjuvant therapies.
Orlandi, A., From controversy to clarity: reimagining the role of CDK4/6 inhibitors in the adjuvant setting– a number needed to treat perspective, <<JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY>>, 2025; 151 (6): N/A-N/A. [doi:10.1007/s00432-025-06229-3] [https://hdl.handle.net/10807/317577]
From controversy to clarity: reimagining the role of CDK4/6 inhibitors in the adjuvant setting– a number needed to treat perspective
Orlandi, Armando
2025
Abstract
Dear Editor, I read with interest the commentary by Tannock et al. titled “Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor” (J Clin Oncol 2025;00:1–5) (Tannock et al. 2025). While the authors raise important concerns regarding toxicity and methodological issues in the monarchE and NATALEE trials, we believe a more nuanced perspective is warranted, particularly when considering the number needed to treat (NNT) in context with other established adjuvant therapies.
| File | Dimensione | Formato | |
|---|---|---|---|
|
s00432-025-06229-3.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
560.34 kB
Formato
Adobe PDF
|
560.34 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
